MiR-101 acts as tumor suppressor in lung and breast cancer, by negatively regulating DNMT3A [63] and EZH2 [64]; miR-193 targets DNMT3A and HDAC in acute myeloid leukemia cells [65]. Here, DNMT3A is linked to neoplasm.